WallStSmart

Nutex Health Inc (NUTX)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 6596% more annual revenue ($56.69B vs $846.72M). NVS leads profitability with a 22.5% profit margin vs 21.2%. NUTX trades at a lower P/E of 7.5x. NUTX earns a higher WallStSmart Score of 63/100 (C+).

NUTX

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 9.5Value: 8.3Quality: 7.5
Piotroski: 4/9Altman Z: 2.49

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NUTXUndervalued (+61.7%)

Margin of Safety

+61.7%

Fair Value

$269.07

Current Price

$200.24

$68.83 discount

UndervaluedFair: $269.07Overvalued
NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NUTX5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Operating MarginProfitability
57.8%10/10

Strong operational efficiency at 57.8%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Profit MarginProfitability
21.2%9/10

Keeps 21 of every $100 in revenue as profit

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

NUTX2 concerns · Avg: 2.5/10
Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-13.6%2/10

Revenue declined 13.6%

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

NUTX profiles as a declining stock while NVS is a value play — different risk/reward profiles.

NUTX carries more volatility with a beta of 2.02 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NUTX scores higher overall (63/100 vs 51/100), backed by strong 21.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?